Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Platinum-Resistant Primary Peritoneal Carcinoma: early-phase trial registry
6 of 10 indexed Platinum-Resistant Primary Peritoneal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Platinum-Resistant Primary Peritoneal Carcinoma: 10 US clinical trials tracked, 6 recruiting.
Platinum-Resistant Primary Peritoneal Carcinoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition platinum-resistant-primary-peritoneal-carcinoma
OPEN 6 | RECR 60% | LATE 0 | EARLY 10 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Platinum-Resistant Primary Peritoneal Carcinoma lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Platinum-Resistant Primary Peritoneal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Platinum-Resistant Primary Peritoneal Carcinoma is recruiting above its size-band peers.
6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Platinum-Resistant Primary Peritoneal Carcinoma research.
Mayo Clinic accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Platinum-Resistant Primary Peritoneal Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 10 trials that report a genuine target (sentinel values excluded). 10 of those (100%) plan for fewer than 100 participants.
-
Platinum-Resistant Primary Peritoneal Carcinoma research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Ira Winer
NCT04055649
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
MacroGenics
NCT06730347
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Ronald Buckanovich
NCT05538091
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
NCT05465941
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
TILT Biotherapeutics
NCT05271318
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
NCT06483048
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT03587311
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Precigen
NCT03907527
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Floor Backes, MD
NCT04781088
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02898207
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Platinum-Resistant Primary Peritoneal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Platinum-Resistant Primary Peritoneal Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Platinum-Resistant Primary Peritoneal Carcinoma page
10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Platinum-Resistant Primary Peritoneal Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Platinum-Resistant Primary Peritoneal Carcinoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Platinum-Resistant Primary Peritoneal Carcinoma condition card totals 10 registered trials; most-linked intervention Paclitaxel; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.